vs
Side-by-side financial comparison of Vita Coco Company, Inc. (COCO) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $179.8M, roughly 1.0× Vita Coco Company, Inc.). Vita Coco Company, Inc. runs the higher net margin — 17.0% vs 0.9%, a 16.0% gap on every dollar of revenue. On growth, Vita Coco Company, Inc. posted the faster year-over-year revenue change (37.3% vs 23.7%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 11.7%).
The Vita Coco Company, doing business simply as Vita Coco, is an American beverage company which mainly sells coconut water. The largest brand globally in coconut/plant waters, Vita Coco has operations in 31 countries as of 2016. It is a benefit corporation. The company is owned by All Market Inc.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
COCO vs FOLD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $179.8M | $185.2M |
| Net Profit | $30.5M | $1.7M |
| Gross Margin | 39.9% | 85.7% |
| Operating Margin | 18.7% | 8.6% |
| Net Margin | 17.0% | 0.9% |
| Revenue YoY | 37.3% | 23.7% |
| Net Profit YoY | 61.4% | -88.5% |
| EPS (diluted) | $0.50 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $179.8M | — | ||
| Q4 25 | $127.8M | $185.2M | ||
| Q3 25 | $182.3M | $169.1M | ||
| Q2 25 | $168.8M | $154.7M | ||
| Q1 25 | $130.9M | $125.2M | ||
| Q4 24 | $127.3M | $149.7M | ||
| Q3 24 | $132.9M | $141.5M | ||
| Q2 24 | $144.1M | $126.7M |
| Q1 26 | $30.5M | — | ||
| Q4 25 | $5.5M | $1.7M | ||
| Q3 25 | $24.0M | $17.3M | ||
| Q2 25 | $22.9M | $-24.4M | ||
| Q1 25 | $18.9M | $-21.7M | ||
| Q4 24 | $3.4M | $14.7M | ||
| Q3 24 | $19.3M | $-6.7M | ||
| Q2 24 | $19.1M | $-15.7M |
| Q1 26 | 39.9% | — | ||
| Q4 25 | 34.9% | 85.7% | ||
| Q3 25 | 37.7% | 88.5% | ||
| Q2 25 | 36.3% | 90.2% | ||
| Q1 25 | 36.7% | 90.7% | ||
| Q4 24 | 32.5% | 90.1% | ||
| Q3 24 | 38.8% | 90.6% | ||
| Q2 24 | 40.8% | 91.1% |
| Q1 26 | 18.7% | — | ||
| Q4 25 | 8.0% | 8.6% | ||
| Q3 25 | 15.3% | 20.3% | ||
| Q2 25 | 14.9% | -6.1% | ||
| Q1 25 | 14.7% | -6.3% | ||
| Q4 24 | 3.4% | 10.7% | ||
| Q3 24 | 15.5% | 15.3% | ||
| Q2 24 | 20.8% | 11.8% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 4.3% | 0.9% | ||
| Q3 25 | 13.2% | 10.2% | ||
| Q2 25 | 13.6% | -15.8% | ||
| Q1 25 | 14.4% | -17.3% | ||
| Q4 24 | 2.6% | 9.8% | ||
| Q3 24 | 14.5% | -4.8% | ||
| Q2 24 | 13.2% | -12.4% |
| Q1 26 | $0.50 | — | ||
| Q4 25 | $0.10 | $0.00 | ||
| Q3 25 | $0.40 | $0.06 | ||
| Q2 25 | $0.38 | $-0.08 | ||
| Q1 25 | $0.31 | $-0.07 | ||
| Q4 24 | $0.06 | $0.05 | ||
| Q3 24 | $0.32 | $-0.02 | ||
| Q2 24 | $0.32 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $352.2M | $274.2M |
| Total Assets | $488.3M | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $201.9M | — | ||
| Q4 25 | $196.9M | $293.5M | ||
| Q3 25 | $203.7M | $263.8M | ||
| Q2 25 | $167.0M | $231.0M | ||
| Q1 25 | $153.6M | $250.6M | ||
| Q4 24 | $164.7M | $249.9M | ||
| Q3 24 | $156.7M | $249.8M | ||
| Q2 24 | $150.1M | $260.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M |
| Q1 26 | $352.2M | — | ||
| Q4 25 | $331.5M | $274.2M | ||
| Q3 25 | $323.7M | $230.4M | ||
| Q2 25 | $296.9M | $204.3M | ||
| Q1 25 | $277.9M | $193.6M | ||
| Q4 24 | $258.8M | $194.0M | ||
| Q3 24 | $252.1M | $178.8M | ||
| Q2 24 | $232.0M | $132.5M |
| Q1 26 | $488.3M | — | ||
| Q4 25 | $461.2M | $949.9M | ||
| Q3 25 | $461.3M | $868.8M | ||
| Q2 25 | $421.1M | $815.3M | ||
| Q1 25 | $384.0M | $789.8M | ||
| Q4 24 | $362.4M | $785.0M | ||
| Q3 24 | $353.1M | $786.6M | ||
| Q2 24 | $323.0M | $749.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $16.3M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 8.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-3.9M | $16.3M | ||
| Q3 25 | $39.1M | $35.7M | ||
| Q2 25 | $21.8M | $-26.5M | ||
| Q1 25 | $-9.8M | $7.8M | ||
| Q4 24 | $6.9M | $-3.9M | ||
| Q3 24 | $9.3M | $-23.0M | ||
| Q2 24 | $26.9M | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-7.1M | $16.0M | ||
| Q3 25 | $35.6M | $35.3M | ||
| Q2 25 | $20.9M | $-28.9M | ||
| Q1 25 | $-10.4M | $7.5M | ||
| Q4 24 | $6.8M | $-4.2M | ||
| Q3 24 | $8.9M | $-23.3M | ||
| Q2 24 | $26.6M | $21.6M |
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | 8.6% | ||
| Q3 25 | 19.6% | 20.9% | ||
| Q2 25 | 12.4% | -18.7% | ||
| Q1 25 | -7.9% | 6.0% | ||
| Q4 24 | 5.3% | -2.8% | ||
| Q3 24 | 6.7% | -16.5% | ||
| Q2 24 | 18.5% | 17.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 0.2% | ||
| Q3 25 | 1.9% | 0.2% | ||
| Q2 25 | 0.6% | 1.6% | ||
| Q1 25 | 0.4% | 0.2% | ||
| Q4 24 | 0.1% | 0.2% | ||
| Q3 24 | 0.3% | 0.3% | ||
| Q2 24 | 0.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | -0.70× | 9.62× | ||
| Q3 25 | 1.63× | 2.06× | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | -0.52× | — | ||
| Q4 24 | 2.05× | -0.27× | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COCO
| Subtotal | $148.2M | 82% |
| Private Label | $24.4M | 14% |
| Other | $7.2M | 4% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
